Prophylaxis of traveler's diarrhea in Egypt: results of a double blind controlled study.
Diarrhea represents the most frequent health problem of Western tourists visiting subtropical and tropical areas. Antibiotic prophylaxis has been suggested by some authors but may not be generally advisable because of adverse drug effects. In the present study we investigated the prophylaxis of traveler's diarrhea using a combination of tannalbuminate and ethacridin-lactate. During a 16-day cruise in Egypt, 77 tourists were assigned to either placebo or prophylactic doses of tannalbuminate (500 mg) and ethacridin-lactate (50 mg), 1 tbl. b.i.d., in a randomized double-blind fashion. The number of bowel movements, consistency of stools, and clinical symptoms like nausea, abdominal cramps, vomiting, and fever were monitored daily. In the placebo group (n = 43) 35 tourists developed diarrhea (81.4%), whereas in the verum group (n = 34) only 18 tourists (52.9%) had diarrhea (p less than 0.0125). In the travelers receiving verum and developing diarrhea the clinical symptoms were less pronounced than in the placebo group. These results demonstrate that the events of traveler's diarrhea may be reduced; moreover, symptoms are attenuated by medical prophylaxis with tannalbuminate and ethacridin-lactate.
Raedsch
R
R
Abteilung für Gastroenterologie, Universität Heidelberg.
Walter-Sack
I
I
Galle
P R
PR
Kommerell
B
B
D000328:Adult; D000930:Antidiarrheals / Q000627:therapeutic use*; D003967:Diarrhea / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004534:Egypt; D004975:Ethacridine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D047348:Hydrolyzable Tannins / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D014195:Travel
D000930:Antidiarrheals; D047348:Hydrolyzable Tannins; D004975:Ethacridine